RxDoctor Payments Data

Paul Caldron

Rheumatology · Phoenix, AZNPI 1366433070

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $29,160 of the $35,615 with a category attached, or 81.9%. 23 manufacturers reported payments, led by Gilead at 44.3% of the total.

$35,615in general payments, 2019–2025

Across 273 payments — averaging $130.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$16K
  • Cardinal Health 108 LLC$11K
  • Johnson & Johnson$5K
  • Amgen$813
  • AbbVie$560
  • Pfizer$521
  • plus $2K from 17 others
$200,168in research payments, 2019–2025

Across 60 payments — averaging $3336.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$59K
  • Astrazeneca UK Limited$40K
  • Eli Lilly$26K
  • Janssen Research & Development, LLC$25K
  • Pfizer$20K
  • Sun Pharmaceutical Industries Inc.$9K
  • plus $21K from 5 others

What the payments were for

  • Consulting fees$29,16082%
  • Travel & lodging$2,3767%
  • Food & beverage$4,07211%
  • Education$70%

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,615 in reported general payments places this provider in the 85th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona

Other rheumatology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →